drugset

drugset / Trial / NCT05960617

Efficacy and Safety of Empagliflozin in GSD-Ib Patients

NCT05960617 ↗

Phase 2 Withdrawn Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

NaSingle-groupOpen-labelTreatment

Summary

Empagliflozin Treatment of GSD-1b patients

Timeline

Start: 2023-07-15
Primary completion: 2024-06-30
Completion: 2024-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Empagliflozin	Small molecule	0.3 mg/kg	Oral

Indications